Media coverage about Entellus Medical (NASDAQ:ENTL) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Entellus Medical earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned media stories about the medical technology company an impact score of 45.7716506484285 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Entellus Medical (NASDAQ ENTL) opened at $24.62 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $25.00. The stock has a market cap of $625.76, a P/E ratio of -19.09 and a beta of 0.02.

A number of brokerages have recently issued reports on ENTL. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. William Blair downgraded shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price objective on the stock in a research report on Monday, October 9th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $17.00 price objective on shares of Entellus Medical in a research report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $20.40.

In related news, Director Brian E. Farley sold 3,972 shares of Entellus Medical stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $19.10, for a total value of $75,865.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Timothy B. Petrick sold 2,000 shares of Entellus Medical stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $20.01, for a total transaction of $40,020.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 166,469 shares of company stock worth $3,682,611. Insiders own 7.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/12/28/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-entellus-medical-entl-share-price.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with Analyst Ratings Network's FREE daily email newsletter.